Quick Answer
Stoke Therapeutics, Inc. reported Operating Income Loss of -$20.59 million for the year ending 2025.
- Stoke Therapeutics, Inc. showed an increase of +79.7% in Operating Income Loss from 2024 to 2025.
- This data is from Stoke Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$1.91 million | Q2 2018: -$3.01 million | Q3 2018: -$3.32 million | Q4 2018: -$4.54 million | Q1 2019: -$6.32 million | Q2 2019: -$8.45 million | Q3 2019: -$9.84 million | Q4 2019: -$11.07 million | Q1 2020: -$11.74 million | Q2 2020: -$13.01 million | Q3 2020: -$13.71 million | Q4 2020: -$14.59 million | Q1 2021: -$16.83 million | Q2 2021: -$22.03 million | Q3 2021: -$22.68 million | Q1 2022: -$24.80 million | Q2 2022: -$25.24 million | Q3 2022: -$27.15 million | Q1 2023: -$24.69 million | Q2 2023: -$33.26 million | Q3 2023: -$27.23 million | Q1 2024: -$28.37 million | Q2 2024: -$29.34 million | Q3 2024: -$30.00 million | Q1 2025: $111.24 million | Q2 2025: -$27.30 million | Q3 2025: -$43.09 million.
- Over the full 8 years of available data (2018 to 2025), Stoke Therapeutics, Inc.'s Operating Income Loss has declined by 61.1%.
- Historical annual values: Fiscal year 2025: -$20.59 million | Fiscal year 2024: -$101.37 million | Fiscal year 2023: -$114.77 million | Fiscal year 2022: -$104.36 million | Fiscal year 2021: -$86.07 million | Fiscal year 2020: -$53.04 million | Fiscal year 2019: -$35.68 million | Fiscal year 2018: -$12.78 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: